Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma

Citation
E. Israel et al., Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in asthma, INT A AL IM, 124(1-3), 2001, pp. 183-186
Citations number
7
Categorie Soggetti
Immunology
Journal title
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
ISSN journal
10182438 → ACNP
Volume
124
Issue
1-3
Year of publication
2001
Pages
183 - 186
Database
ISI
SICI code
1018-2438(200101/03)124:1-3<183:EOPOTB>2.0.ZU;2-F
Abstract
Background: Regular use of inhaled beta -adrenergic agonists may have adver se effects in some asthma patients. Polymorphisms of the beta (2)-adrenergi c receptor (beta (2)-AR) can affect its regulation; however, results of sma ller studies of the effects of such polymorphisms on response to beta -agon ist therapy have been inconsistent. Methods: We examined the possible effec ts of polymorphisms at codons 16 (beta (2)-AR-16) and 27 (beta (2)-AR-27) o n response to albuterol by genotyping 190 asthmatics who had participated i n a trial of regular versus as-needed albuterol use. Results: During the 16 -week treatment period, patients homozygous for arginine (Arg/Arg) at beta (2)-AR-16 who used albuterol regularly had a small decline in morning peak expiratory flow (AM PEF). Th is effect was magnified during a 4-week run-ou t period, when all patients returned to as-needed albuterol only. By the en d of the study, Arg/Arg subjects who had used albuterol regularly had an AM PEF 30.5 +/- 12.1 liters/min lower (p = 0.012) than Arg/Arg patients who h ad used albuterol as needed only. Subjects homozygous for glycine at beta ( 2)-AR-16 showed no such decline. Evening PEF also declined in the Arg/Arg r egular but not in as-need albuterol users. No significant differences betwe en regular and asneeded treatment were associated with polymorphisms at bet a (2)-AR-27. Conclusions: Polymorphisms of the beta (2)-AR may influence ai rway responses to regular inhaled beta -agonist treatment. Copyright (C) 20 01 S. Karger AG, Basel.